Axonis Therapeutics, Inc.
Boston, MA Axonis Therapeutics, Inc.
- UEI
- LR1MVZHCSJ95
- CAGE
- 8EMJ2
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- Tufts Launchpad, 75 Kneeland St 14th floor, Boston, MA 02111, USA
- Website
- axonis.us
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 96 Administration of Economic Programs
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Axonis Therapeutics, Inc.
Axonis Therapeutics, Inc. is a biotechnology company focused on developing innovative neurological treatments, specifically targeting neurological disorders through advanced pharmaceutical research and development. Registered in SAM.gov since October 2019, the company is a for-profit corporate entity headquartered in Boston, Massachusetts. The organization specializes in developing novel therapeutic compounds and gene therapies that target the KCC2 chloride transporter, with a primary focus on creating potential treatments for neurological conditions such as epilepsy, spinal cord injury, diabetic neuropathy, and glaucoma.
Through federal grant awards, Axonis Therapeutics has consistently secured funding from multiple federal agencies to advance its neurological research and development efforts. The National Institute of Neurological Disorders and Stroke (NINDS) has been a primary funding source, supporting multiple projects including the development of oral KCC2 potentiator compounds for treating mesial temporal lobe epilepsy and developing neuromodulating therapies for spinal cord injury. Additional funding has come from the National Eye Institute for glaucoma gene therapy research, the National Institute of Diabetes and Digestive and Kidney Diseases for diabetic neuropathy treatment, and the Department of Army Medical Command for research on spinal cord injury recovery and neuropathic pain reduction. These Phase I and Phase II SBIR (Small Business Innovation Research) grants, ranging from approximately $300,000 to $350,000, demonstrate Axonis Therapeutics' commitment to translational research aimed at developing first-in-class therapies for complex neurological conditions with significant unmet medical needs.
Quick answers
What is Axonis Therapeutics, Inc.'s UEI?
Axonis Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is LR1MVZHCSJ95.
What is Axonis Therapeutics, Inc.'s CAGE code?
Axonis Therapeutics, Inc.'s CAGE code is 8EMJ2.
Where is Axonis Therapeutics, Inc. located?
Axonis Therapeutics, Inc.'s physical address in SAM.gov is Tufts Launchpad, 75 Kneeland St 14th floor, Boston, MA 02111, USA.
Is Axonis Therapeutics, Inc. registered in SAM.gov?
Yes. Axonis Therapeutics, Inc.'s SAM.gov registration is active through March 31, 2027.
What is Axonis Therapeutics, Inc.'s most recent federal award?
Axonis Therapeutics, Inc.'s most recent federal grant award is Development of oral KCC2 potentiator AXN-027 as a novel anti-epileptic drug for mesial temporal lobe epilepsy -… (R43NS137942), from National Institute of Neurological Disorders and Stroke, on September 1, 2024.
On GovTribe
See Axonis Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors